icodextrin: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321	NDA	Vantive US Healthcare LLC	0941-0679-05	2500 mL in 1 BAG (0941-0679-05)	2002-12-20
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321	NDA	Vantive US Healthcare LLC	0941-0679-06	2000 mL in 1 BAG (0941-0679-06)	2002-12-20
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321	NDA	Vantive US Healthcare LLC	0941-0679-52	2000 mL in 1 BAG (0941-0679-52)	2002-12-20
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321	NDA	Vantive US Healthcare LLC	0941-0679-53	2500 mL in 1 BAG (0941-0679-53)	2002-12-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Icodextrin, a glucose polymer used in medical solutions, relies on a specialized supply chain for its production and distribution. The synthesis of icodextrin involves the enzymatic degradation of starch, requiring specific enzymes and controlled manufacturing processes. Key suppliers provide raw materials, specialized reagents, and contract manufacturing services to pharmaceutical companies producing icodextrin-based products, such as those used in peritoneal dialysis.

What are the primary components in icodextrin production?

The synthesis of icodextrin involves several key components and processes. The primary starting material is starch, typically derived from corn or potato. This starch undergoes enzymatic hydrolysis to produce a mixture of glucose polymers.

Starch: The foundation of icodextrin. The source and purity of starch are critical to the final product's characteristics.
Enzymes: Specific enzymes, primarily alpha-amylases and cyclodextrin glucanotransferases (CGTases), are essential for breaking down starch into the desired oligosaccharide mixture. The selection of enzyme type and activity level dictates the molecular weight distribution of the resulting icodextrin.
Purification Agents: Following enzymatic synthesis, the crude icodextrin solution requires purification to remove unreacted starch, enzymes, and other byproducts. This often involves filtration, chromatography, and precipitation steps.
Solvents and Buffers: Water is the primary solvent. Buffers are used to maintain optimal pH for enzymatic reactions and purification steps.

Who are the key raw material suppliers for icodextrin?

The raw material supply chain for icodextrin is characterized by a need for high-purity starches and specialized enzymes. While specific supplier relationships are often proprietary, the market segments for these materials are well-defined.

Starch Suppliers:

Ingredion: A global leader in ingredient solutions, Ingredion provides a range of starches from various botanical sources, including corn and tapioca. They supply starches that meet the stringent purity requirements for pharmaceutical applications. Their operations span North America, South America, Europe, and Asia.
Cargill: Another major agribusiness company, Cargill produces and supplies starches and starch derivatives for food and industrial applications. Their pharmaceutical-grade starches are utilized in various drug formulations. Cargill has a global presence with significant operations in North America and Europe.
ADM (Archer Daniels Midland): ADM is a global food processing and commodities trading corporation that also supplies pharmaceutical-grade starches. Their extensive agricultural supply chain ensures consistent quality and availability. ADM's presence is worldwide, with major hubs in North America and Europe.

Enzyme Suppliers:

Novozymes: A leading global enzyme producer, Novozymes develops and manufactures a wide array of industrial enzymes, including those suitable for carbohydrate modification. Their enzymatic solutions are used in various biopharmaceutical manufacturing processes. Novozymes is headquartered in Denmark and operates globally.
DSM: Royal DSM is a Dutch multinational corporation active in nutrition, health, and bioscience. DSM offers enzyme solutions for bioprocessing, including enzymes for starch modification. Their research and development in biocatalysis are significant. DSM has a global manufacturing and sales network.
BASF: While known for its broad chemical portfolio, BASF also offers enzyme solutions through its Nutrition & Health division, which can include enzymes used in pharmaceutical ingredient manufacturing. BASF is a German multinational with a vast global footprint.

What are the challenges in securing a reliable icodextrin supply?

Securing a reliable supply of icodextrin involves navigating several critical challenges, from raw material sourcing to manufacturing capacity and regulatory compliance.

Raw Material Volatility: The price and availability of agricultural commodities like corn and potatoes, the source of starch, can fluctuate due to weather patterns, geopolitical events, and global demand. This volatility directly impacts production costs for icodextrin manufacturers. For example, a severe drought in a major corn-producing region can significantly increase starch prices.
Specialized Enzyme Production: The production of specific enzymes required for icodextrin synthesis is a specialized biotechnological process. Limited numbers of enzyme manufacturers possess the expertise and facilities to produce pharmaceutical-grade enzymes at scale, potentially creating bottlenecks if demand surges or a key supplier experiences production issues.
Quality Control and Purity: Pharmaceutical-grade icodextrin demands exceptionally high purity. Maintaining consistent quality across batches requires rigorous quality control measures at every stage, from raw material sourcing to final product testing. Any deviation can lead to batch rejection and supply chain disruptions. The pharmacopoeial standards (e.g., USP, EP) for icodextrin purity are stringent, requiring low levels of residual sugars and other impurities.
Manufacturing Capacity: The synthesis and purification of icodextrin are complex processes requiring specialized equipment and controlled environments. Pharmaceutical companies or their contract manufacturers must maintain sufficient production capacity to meet market demand. Expanding this capacity can be time-consuming and capital-intensive.
Regulatory Compliance: The pharmaceutical industry is heavily regulated. Manufacturers of icodextrin and its precursors must adhere to Good Manufacturing Practices (GMP) and obtain necessary regulatory approvals for their production facilities and processes. Changes in regulations or the need for revalidation can impact supply continuity.

Which contract manufacturing organizations (CMOs) are involved in icodextrin production?

The production of icodextrin, particularly the synthesis and purification of the active pharmaceutical ingredient (API), is often outsourced to specialized Contract Manufacturing Organizations (CMOs). These CMOs possess the necessary expertise, equipment, and regulatory compliance to handle complex biopharmaceutical manufacturing.

While specific CMOs directly manufacturing icodextrin as an API are not always publicly disclosed due to confidentiality agreements, companies specializing in carbohydrate chemistry and pharmaceutical ingredient synthesis are primary candidates.

Potential CMOs with relevant capabilities include:

Carbomer, Inc.: This company has a history of specializing in carbohydrate-based polymers and excipients for the pharmaceutical industry. Their expertise in polymer synthesis and purification could extend to icodextrin. Carbomer has manufacturing facilities in the United States.
Associated British Foods (ABF) Ingredients: Through its subsidiaries, ABF Ingredients offers a range of specialty ingredients, including those derived from carbohydrates. Their capacity for industrial-scale bioprocessing and purification makes them a potential partner for icodextrin production. ABF operates globally with significant manufacturing presence in Europe and North America.
Corn Products International (now Ingredion): While primarily a raw material supplier, large ingredient manufacturers sometimes offer contract manufacturing services for their specialized derivatives. Ingredion's extensive starch processing capabilities could be leveraged for icodextrin synthesis under contract.

Key considerations when selecting an icodextrin CMO:

GMP Compliance: The CMO must have a robust GMP-compliant manufacturing environment.
Technical Expertise: Proven experience in enzymatic synthesis, carbohydrate chemistry, and large-scale purification is critical.
Analytical Capabilities: Strong in-house analytical testing for product characterization and quality control.
Regulatory Track Record: A history of successful regulatory inspections and product approvals.
Capacity and Scalability: The ability to meet current and future demand.

What are the regulatory considerations for icodextrin drug products?

The regulatory landscape for icodextrin-based drug products is stringent, primarily due to their use in medical applications, particularly parenteral administration. Manufacturers must adhere to comprehensive guidelines set by global health authorities.

Key regulatory aspects include:

API Manufacturing Standards: The icodextrin active pharmaceutical ingredient (API) must be manufactured in compliance with current Good Manufacturing Practices (cGMP). This involves stringent controls over facilities, equipment, personnel, processes, and quality systems.
Pharmacopoeial Standards: Icodextrin products must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define criteria for identity, purity, strength, and quality, including limits for specific impurities and endotoxins. For instance, the USP monograph for Icodextrin typically specifies limits for glucose, maltose, and dextrins.
Drug Product Formulation and Manufacturing: The final drug product, such as an intravenous solution or peritoneal dialysis solution, must also be manufactured under cGMP. This includes sterile processing for parenteral products, validated sterilization methods, and control of particulate matter.
Stability Testing: Comprehensive stability studies are required to determine the shelf-life of both the API and the finished drug product under various storage conditions. This data supports the expiry dating of the product.
Impurity Profiling: Thorough characterization and control of process-related impurities and degradation products are essential. Regulatory agencies require a detailed understanding of the impurity profile and justification for acceptable limits.
Country-Specific Approvals: Pharmaceutical companies must obtain marketing authorization from regulatory agencies in each country where the icodextrin drug product will be sold. This typically involves submitting a comprehensive dossier (e.g., New Drug Application in the US, Marketing Authorisation Application in Europe) detailing all aspects of the product's development, manufacturing, quality control, and clinical efficacy and safety.
Post-Market Surveillance: Once approved, manufacturers are responsible for ongoing pharmacovigilance, including monitoring adverse events and reporting them to regulatory authorities.

What is the global market for icodextrin and its key therapeutic uses?

Icodextrin, primarily formulated as a solution for peritoneal dialysis, serves a significant therapeutic market for patients with end-stage renal disease (ESRD). Its osmotic properties make it an effective agent for fluid removal and solute clearance in peritoneal dialysis.

Key Therapeutic Uses:

Peritoneal Dialysis (PD): This is the dominant application for icodextrin. Icodextrin solutions are used as the dialysate during long peritoneal dialysis dwell times, particularly overnight. They are effective in removing excess fluid and uremic toxins by creating a sustained osmotic gradient across the peritoneal membrane. Icodextrin is preferred for its lower incidence of hyperglycemia compared to dextrose-based solutions and its ability to provide sustained ultrafiltration.
Intravenous Fluid Management (Less Common): In some specific clinical settings, icodextrin has been explored for intravenous fluid resuscitation and management, leveraging its osmotic properties for volume expansion. However, this application is less established than its use in PD.

Market Dynamics:

Prevalence of ESRD: The global incidence and prevalence of ESRD are increasing due to factors such as aging populations, rising rates of diabetes and hypertension. This drives demand for dialysis modalities, including PD.
Shift Towards Home Dialysis: There is a growing trend towards home-based dialysis treatments, including PD, which offers patients greater flexibility and potentially better quality of life. This trend directly benefits the market for PD solutions like icodextrin.
Competitive Landscape: The PD fluid market is competitive, with dextrose-based solutions being the traditional standard. However, icodextrin has carved out a significant niche due to its advantages in fluid removal and glycemic control.
Geographic Markets: Major markets for icodextrin are regions with high ESRD prevalence and established PD programs, including North America, Europe, and parts of Asia.
Pricing and Reimbursement: Pricing and reimbursement policies for dialysis treatments and associated supplies significantly influence market access and demand for icodextrin products.

The global market for icodextrin is intrinsically linked to the broader nephrology market and the adoption rates of peritoneal dialysis as a treatment option for ESRD.

Key Takeaways

Icodextrin production relies on a supply chain involving high-purity starch, specialized enzymes, and sophisticated purification processes.
Key raw material suppliers include global agribusiness and biotechnology firms.
Challenges in the supply chain include raw material volatility, specialized enzyme production, stringent quality control, manufacturing capacity, and regulatory compliance.
Contract Manufacturing Organizations (CMOs) with expertise in carbohydrate chemistry and pharmaceutical API synthesis are crucial for icodextrin production.
Regulatory oversight by bodies like the FDA and EMA mandates adherence to cGMP, pharmacopoeial standards, and comprehensive product dossiers.
The primary therapeutic use of icodextrin is in peritoneal dialysis solutions for end-stage renal disease, a market influenced by the growing prevalence of ESRD and the shift towards home dialysis.

Frequently Asked Questions

What is the primary difference between icodextrin and dextrose in peritoneal dialysis solutions? Icodextrin is a glucose polymer, while dextrose is a simple sugar. In peritoneal dialysis, icodextrin creates a sustained osmotic gradient for ultrafiltration, leading to more effective fluid removal over longer dwell times and with a lower risk of hyperglycemia compared to dextrose.
Are there specific geographical regions with higher demand for icodextrin? Yes, regions with higher incidences of end-stage renal disease and well-established peritoneal dialysis programs, such as North America, Europe, and certain parts of Asia, exhibit higher demand for icodextrin.
What are the main quality control parameters for pharmaceutical-grade icodextrin? Key quality control parameters include identity testing, purity (assessing residual glucose, maltose, and other oligosaccharides), molecular weight distribution, endotoxin levels, and sterility for the final drug product.
Can icodextrin be synthesized using simpler starch processing methods? While icodextrin is derived from starch, its specific molecular weight distribution and purity require controlled enzymatic hydrolysis using specific enzymes like cyclodextrin glucanotransferases (CGTases) under precise conditions. Simpler starch processing methods would not yield a product with the required pharmaceutical specifications.
What is the typical shelf life of icodextrin-based peritoneal dialysis solutions? The shelf life of icodextrin-based peritoneal dialysis solutions is typically determined by extensive stability studies and can range from 18 to 36 months when stored under recommended conditions.

Citations

[1] United States Pharmacopeial Convention. (n.d.). USP Monograph: Icodextrin. Retrieved from [USP website] (Note: Actual access requires subscription; general reference to the existence of the monograph).

[2] European Pharmacopoeia. (n.d.). Ph. Eur. Monograph: Icodextrin. Retrieved from [EDQM website] (Note: Actual access requires subscription; general reference to the existence of the monograph).

[3] Novozymes. (n.d.). Enzymes for Carbohydrate Modification. Retrieved from Novozymes official website.

[4] DSM. (n.d.). Enzymes for Bioprocessing. Retrieved from DSM official website.

[5] Ingredion. (n.d.). Starches for Pharmaceutical Applications. Retrieved from Ingredion official website.

[6] Cargill. (n.d.). Pharmaceutical Ingredients. Retrieved from Cargill official website.

[7] Archer Daniels Midland Company. (n.d.). Specialty Ingredients for Pharma. Retrieved from ADM official website.

Suppliers and packagers for generic pharmaceutical drug: icodextrin

icodextrin

Icodextrin Drug Supply Chain Analysis